Key Points
- Insider sale: Director Karen Foster sold 96,923 shares on March 5 at an average price of $20.15 for a total of $1,952,998.45, reducing her stake by 46.01% to 113,742 shares valued at $2,291,901.30.
- Company and ownership snapshot: BLFS opened at $19.90 (12‑month range $19.10–$29.62) with a market cap of $961.2M and institutional investors holding 93.24%, including T. Rowe Price's 5.18M‑share stake after a sizable increase.
- Analyst view: The stock has a consensus rating of "Moderate Buy" and a $32.00 target, though opinions are mixed—several firms upgraded to buy/strong‑buy while Weiss Ratings remains a "sell (d-)."
BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Karen Foster sold 96,923 shares of the business's stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $20.15, for a total value of $1,952,998.45. Following the completion of the sale, the insider owned 113,742 shares of the company's stock, valued at $2,291,901.30. This trade represents a 46.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
BioLife Solutions Price Performance
BioLife Solutions stock opened at $19.90 on Tuesday. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.62. The company has a fifty day moving average price of $23.26 and a two-hundred day moving average price of $25.03. The company has a market cap of $961.17 million, a PE ratio of -180.89 and a beta of 1.90.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of BioLife Solutions from a "hold" rating to a "buy" rating in a research note on Saturday, February 28th. UBS Group reaffirmed a "buy" rating on shares of BioLife Solutions in a report on Monday, December 29th. Zacks Research upgraded BioLife Solutions from a "hold" rating to a "strong-buy" rating in a research report on Friday, January 23rd. Northland Securities set a $34.00 price target on BioLife Solutions in a report on Monday, January 5th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $32.00.
Get Our Latest Stock Analysis on BLFS
Institutional Investors Weigh In On BioLife Solutions
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. boosted its stake in BioLife Solutions by 27.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider's stock valued at $125,273,000 after purchasing an additional 1,113,972 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of BioLife Solutions by 9.2% in the fourth quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider's stock valued at $95,080,000 after buying an additional 332,747 shares during the period. XTX Topco Ltd boosted its stake in BioLife Solutions by 280.4% during the fourth quarter. XTX Topco Ltd now owns 36,262 shares of the medical equipment provider's stock valued at $877,000 after buying an additional 26,729 shares in the last quarter. SummitTX Capital L.P. bought a new position in BioLife Solutions during the fourth quarter valued at about $1,747,000. Finally, Sandler Capital Management acquired a new position in BioLife Solutions during the fourth quarter worth about $765,000. Institutional investors own 93.24% of the company's stock.
About BioLife Solutions
(
Get Free Report)
BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife's product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.
The company's flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
